754 related articles for article (PubMed ID: 23061882)
1. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
Braza MS; Klein B
Br J Haematol; 2013 Jan; 160(2):123-32. PubMed ID: 23061882
[TBL] [Abstract][Full Text] [Related]
2. [Tgammadelta lymphocytes in oncology: unconventional killer lymphocytes].
Catros V; Toutirais O; Bouet F; Cabillic F; Desille M; Fournié JJ
Med Sci (Paris); 2010 Feb; 26(2):185-91. PubMed ID: 20188051
[TBL] [Abstract][Full Text] [Related]
3. The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting.
Li Y; Li G; Zhang J; Wu X; Chen X
Front Immunol; 2020; 11():619954. PubMed ID: 33664732
[TBL] [Abstract][Full Text] [Related]
4. Induction of cytotoxic T lymphocytes by CEA peptide-pulsed γδ T-cells isolated from patients with advanced cancer.
Yamasaki A; Onishi H; Morisaki T; Katano M
Anticancer Res; 2011 Jul; 31(7):2419-24. PubMed ID: 21873153
[TBL] [Abstract][Full Text] [Related]
5. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C
Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.
Poccia F; Gioia C; Martini F; Sacchi A; Piacentini P; Tempestilli M; Agrati C; Amendola A; Abdeddaim A; Vlassi C; Malkovsky M; D'Offizi G
AIDS; 2009 Mar; 23(5):555-65. PubMed ID: 19238075
[TBL] [Abstract][Full Text] [Related]
7. gammadelta T cells in cancer immunotherapy: current status and future prospects.
Chiplunkar S; Dhar S; Wesch D; Kabelitz D
Immunotherapy; 2009 Jul; 1(4):663-78. PubMed ID: 20635991
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells.
Stewart TJ; Smyth MJ; Fernando GJ; Frazer IH; Leggatt GR
Cancer Res; 2003 Jun; 63(12):3058-60. PubMed ID: 12810627
[TBL] [Abstract][Full Text] [Related]
9. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes.
Poccia F; Cipriani B; Vendetti S; Colizzi V; Poquet Y; Battistini L; López-Botet M; Fournié JJ; Gougeon ML
J Immunol; 1997 Dec; 159(12):6009-17. PubMed ID: 9550399
[TBL] [Abstract][Full Text] [Related]
10. Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vγ9Vδ2 T cells, αβ CD8+ T cells, regulatory T cells, and dendritic cells.
Castella B; Riganti C; Fiore F; Pantaleoni F; Canepari ME; Peola S; Foglietta M; Palumbo A; Bosia A; Coscia M; Boccadoro M; Massaia M
J Immunol; 2011 Aug; 187(4):1578-90. PubMed ID: 21753152
[TBL] [Abstract][Full Text] [Related]
11. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
[TBL] [Abstract][Full Text] [Related]
12. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.
Gomes AQ; Martins DS; Silva-Santos B
Cancer Res; 2010 Dec; 70(24):10024-7. PubMed ID: 21159627
[TBL] [Abstract][Full Text] [Related]
13. Shared reactivity of V{delta}2(neg) {gamma}{delta} T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells.
Halary F; Pitard V; Dlubek D; Krzysiek R; de la Salle H; Merville P; Dromer C; Emilie D; Moreau JF; Déchanet-Merville J
J Exp Med; 2005 May; 201(10):1567-78. PubMed ID: 15897274
[TBL] [Abstract][Full Text] [Related]
14. [New insights into cytotoxic effector cells].
Rey J; Olive D; Sébahoun G; O'Callaghan T; Costello RT
Bull Cancer; 2005 Nov; 92(11):935-43. PubMed ID: 16316827
[TBL] [Abstract][Full Text] [Related]
15. Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies.
Martinet L; Poupot R; Fournié JJ
Immunol Lett; 2009 May; 124(1):1-8. PubMed ID: 19465238
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
[TBL] [Abstract][Full Text] [Related]
17. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
18. [Antitumor immunity and cellular cancer therapies].
Catros-Quemener V; Bouet F; Genetet N
Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191
[TBL] [Abstract][Full Text] [Related]
19. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
[TBL] [Abstract][Full Text] [Related]
20. Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes.
Kiladjian JJ; Visentin G; Viey E; Chevret S; Eclache V; Stirnemann J; Bourhis JH; Chouaib S; Fenaux P; Caignard A
Haematologica; 2008 Mar; 93(3):381-9. PubMed ID: 18268282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
